Category: biotech

.After a few years in biotech, Mike Quigley, Ph.D., is going back to the pharma fold, taking up the best scientific research place at Sanofi.Quigley

.Sanofi has made a late access to the radioligand party, paying one hundred thousand euros ($ 110 million) beforehand for international civil liberties to a

.Sanofi has stopped a stage 2 difficulty of Denali Therapeutics-partnered oditrasertib in a number of sclerosis. The French drugmaker tore the RIPK1 inhibitor ordeal from

.Sangamo Therapies has determined a shortcut to market for its Fabry ailment applicant, straightening along with the FDA on a path that might slash three

.Sage Therapeutics’ most up-to-date attempt to diminish its pipeline and also staff are going to see a third of the biotech’s staff members going to

.Matt Gline is actually back along with a new ‘vant’ business, after the Roivant Sciences CEO spent Bayer $14 million upfront for the liberties to

.Roche has returned the legal rights to UCB’s anti-tau antibody bepranemab, bowing out a $120 thousand bank on the Alzheimer’s health condition drug candidate on

.Roche is holding out hopes that its own injectable being overweight prospect might ultimately display 25% effective weight loss in late-stage trials, the pharma’s head

.Roche’s chronic cough system has sputtered to a halt. The drugmaker, which axed the system after the medication candidate let down in period 2, revealed

.After forming a gene treatment collaboration with Dyno Rehabs in 2020, Roche is back for even more.In a new bargain possibly worth more than $1